Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.
Crismale JF, Martel-Laferrière V, Bichoupan K, Schonfeld E, Pappas A, Wyatt C, Odin JA, Liu LU, Schiano TD, Perumalswami PV, Bansal M, Dieterich DT, Branch AD.
Crismale JF, et al. Among authors: branch ad.
Liver Int. 2014 Aug;34(7):1018-24. doi: 10.1111/liv.12342. Epub 2013 Oct 25.
Liver Int. 2014.
PMID: 24118693
Free PMC article.